TY  - CONF

T1  - A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2013/05/20

AU  - Wolin EM

AU  - Jarzab B

AU  - Eriksson B

AU  - Walter T

AU  - Toumpanakis C

AU  - Morse M

AU  - Tomassetti P

AU  - Weber M

AU  - Fogelman DR

AU  - Ramage J

AU  - Poon D et al

ED  - 

VL  - 31

IS  - 15

Y2  - 2024/12/26

ER  -